<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116975">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580241</url>
  </required_header>
  <id_info>
    <org_study_id>2606</org_study_id>
    <nct_id>NCT01580241</nct_id>
  </id_info>
  <brief_title>Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer</brief_title>
  <official_title>Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients
      with pancreatic cancer. The investigators would like to analyze its expression pre and post
      treatment, to gauge the correlation between current pancreatic cancer therapies and the
      expression of DCAMKL-1
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Surgery group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo surgical treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo chemotherapy treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant group</arm_group_label>
    <description>Patients with pancreatic cancer who undergo surgery followed by chemotherapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We
        will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy
        only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a
        change in DCAMKl-1 expression.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pancreatic cancer

        Exclusion Criteria:

          -  age &lt; 18, history of other types of cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney Houchen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stephensen Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 2, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
